Chamberlain University
LANIF • 665 RN
★ ★
C College of Nursing & Public Health
J O U R N E Y T O E X T R A O R D I N A R Y CO M PA S S I O N AT E C A R E
EST. 1889
NR 566 — Final Examination
CO M P R E H E N S I V E P H A R M A CO LO G Y: R E P R O D U C T I V E , N E U R O LO G I C , P SYC H I AT R I C & I N F E C T I O U S
DISEASE
INSTITUTION Chamberlain University COURSE CODE NR 566
PROGRAM Master of Science in Nursing (MSN / FNP) ACADEMIC YEAR
EXAM TITLE Final Examination — Comprehensive TOTAL QUESTIONS 50 Questions
Review
COURSE TITLE Advanced Pharmacology for Care of the FORMAT Multiple Choice — Select the Single Best
Family Answer
EXAMINATION INSTRUCTIONS
▸ Select the single best answer for each question based on evidence-based pharmacology.
▸ Drug classifications, mechanisms of action, contraindications, and adverse effects are all testable content.
▸ Population-specific considerations (pregnancy, elderly, renal/hepatic impairment) are emphasized.
▸ Correct answers and clinical rationales appear below each question for board review purposes.
▸ All pharmacological data reflects current clinical guidelines and FDA-approved indications.
SECTION I — REPRODUCTIVE & ENDOCRINE PHARMACOLOGY Questions 1 – 14
1. A postmenopausal woman with osteoporosis is concerned about the risks of hormone replacement therapy. Which
medication classes are considered alternatives to HRT for osteoporosis management?
A. SSRIs and SNRIs
B. Raloxifene (Evista) and bisphosphonates (alendronate, calcitonin)
C. Oral contraceptives and progestins
D. Androgens and anabolic steroids
CORRECT ANSWER B — Raloxifene (Evista) and bisphosphonates (alendronate, calcitonin)
RATIONALE Raloxifene (SERM) and bisphosphonates (alendronate, calcitonin) are established non-hormonal alternatives
for osteoporosis. They provide bone protection without the cardiovascular and breast cancer risks associated
with traditional HRT.
, 2. Which three medications are classified as Selective Estrogen Receptor Modulators (SERMs), and what is their
primary therapeutic advantage?
A. Estradiol, estropipate, conjugated estrogens — pure estrogen effects
B. Tamoxifen, toremifene, and raloxifene — provide estrogen benefits while avoiding drawbacks
C. Medroxyprogesterone, norethindrone, levonorgestrel — oppose estrogen effects
D. Clomiphene, letrozole, anastrozole — stimulate ovulation
CORRECT ANSWER B — Tamoxifen, toremifene, and raloxifene
RATIONALE SERMs act as estrogen agonists in some tissues (bone, liver) and antagonists in others (breast, uterus),
providing beneficial effects while avoiding estrogen's adverse effects.
3. A patient presents with dysfunctional uterine bleeding (DUB). What is the standard pharmacologic treatment
regimen?
A. 5-day course of estrogen
B. 10-14 day course of progestin
C. Continuous daily combined OCP
D. Immediate D&C
CORRECT ANSWER B — 10-14 day course of progestin
RATIONALE DUB is managed with a 10-14 day course of progestin, which stabilizes the endometrium and induces a
controlled withdrawal bleed, resolving irregular bleeding patterns.
4. For a patient with amenorrhea and low estrogen levels, what is the appropriate progestin regimen to induce
menstrual flow?
A. Continuous progestin for 30 days
B. Progestin for 5-10 days
C. Estrogen alone for 21 days
D. Combined OCP for 3 months
CORRECT ANSWER B — Progestin for 5-10 days
RATIONALE In patients with low estrogen levels, progestin administered for 5-10 days induces withdrawal bleeding,
confirming adequate endometrial priming and helping differentiate causes of amenorrhea.
5. What protective effect does long-term progestin therapy provide?
A. Protection against breast cancer
B. Protection against endometrial cancer
C. Protection against ovarian cancer
D. Protection against cardiovascular disease
CORRECT ANSWER B — Protection against endometrial cancer
RATIONALE Long-term progestin therapy counteracts unopposed estrogen's proliferative effects on the endometrium,
preventing endometrial hyperplasia and reducing endometrial cancer risk.
LANIF • 665 RN
★ ★
C College of Nursing & Public Health
J O U R N E Y T O E X T R A O R D I N A R Y CO M PA S S I O N AT E C A R E
EST. 1889
NR 566 — Final Examination
CO M P R E H E N S I V E P H A R M A CO LO G Y: R E P R O D U C T I V E , N E U R O LO G I C , P SYC H I AT R I C & I N F E C T I O U S
DISEASE
INSTITUTION Chamberlain University COURSE CODE NR 566
PROGRAM Master of Science in Nursing (MSN / FNP) ACADEMIC YEAR
EXAM TITLE Final Examination — Comprehensive TOTAL QUESTIONS 50 Questions
Review
COURSE TITLE Advanced Pharmacology for Care of the FORMAT Multiple Choice — Select the Single Best
Family Answer
EXAMINATION INSTRUCTIONS
▸ Select the single best answer for each question based on evidence-based pharmacology.
▸ Drug classifications, mechanisms of action, contraindications, and adverse effects are all testable content.
▸ Population-specific considerations (pregnancy, elderly, renal/hepatic impairment) are emphasized.
▸ Correct answers and clinical rationales appear below each question for board review purposes.
▸ All pharmacological data reflects current clinical guidelines and FDA-approved indications.
SECTION I — REPRODUCTIVE & ENDOCRINE PHARMACOLOGY Questions 1 – 14
1. A postmenopausal woman with osteoporosis is concerned about the risks of hormone replacement therapy. Which
medication classes are considered alternatives to HRT for osteoporosis management?
A. SSRIs and SNRIs
B. Raloxifene (Evista) and bisphosphonates (alendronate, calcitonin)
C. Oral contraceptives and progestins
D. Androgens and anabolic steroids
CORRECT ANSWER B — Raloxifene (Evista) and bisphosphonates (alendronate, calcitonin)
RATIONALE Raloxifene (SERM) and bisphosphonates (alendronate, calcitonin) are established non-hormonal alternatives
for osteoporosis. They provide bone protection without the cardiovascular and breast cancer risks associated
with traditional HRT.
, 2. Which three medications are classified as Selective Estrogen Receptor Modulators (SERMs), and what is their
primary therapeutic advantage?
A. Estradiol, estropipate, conjugated estrogens — pure estrogen effects
B. Tamoxifen, toremifene, and raloxifene — provide estrogen benefits while avoiding drawbacks
C. Medroxyprogesterone, norethindrone, levonorgestrel — oppose estrogen effects
D. Clomiphene, letrozole, anastrozole — stimulate ovulation
CORRECT ANSWER B — Tamoxifen, toremifene, and raloxifene
RATIONALE SERMs act as estrogen agonists in some tissues (bone, liver) and antagonists in others (breast, uterus),
providing beneficial effects while avoiding estrogen's adverse effects.
3. A patient presents with dysfunctional uterine bleeding (DUB). What is the standard pharmacologic treatment
regimen?
A. 5-day course of estrogen
B. 10-14 day course of progestin
C. Continuous daily combined OCP
D. Immediate D&C
CORRECT ANSWER B — 10-14 day course of progestin
RATIONALE DUB is managed with a 10-14 day course of progestin, which stabilizes the endometrium and induces a
controlled withdrawal bleed, resolving irregular bleeding patterns.
4. For a patient with amenorrhea and low estrogen levels, what is the appropriate progestin regimen to induce
menstrual flow?
A. Continuous progestin for 30 days
B. Progestin for 5-10 days
C. Estrogen alone for 21 days
D. Combined OCP for 3 months
CORRECT ANSWER B — Progestin for 5-10 days
RATIONALE In patients with low estrogen levels, progestin administered for 5-10 days induces withdrawal bleeding,
confirming adequate endometrial priming and helping differentiate causes of amenorrhea.
5. What protective effect does long-term progestin therapy provide?
A. Protection against breast cancer
B. Protection against endometrial cancer
C. Protection against ovarian cancer
D. Protection against cardiovascular disease
CORRECT ANSWER B — Protection against endometrial cancer
RATIONALE Long-term progestin therapy counteracts unopposed estrogen's proliferative effects on the endometrium,
preventing endometrial hyperplasia and reducing endometrial cancer risk.
